Report Conveys Value and Threats of Nanotechnology Research
|
By LabMedica International staff writers Posted on 04 Feb 2013 |
While scientists constantly increase their knowledge of biology and the surrounding world, all this newly gleaned information has the potential to advance healthcare, it is also possible that the same discoveries can also be used in ways that cause extensive havoc.
A new report assessed the potential for nanosized particles to break the blood-brain barrier (BBB), the closely-knit layers of cells that provide the brain with the highest level of protection in the human body. Some neuroscientists are modifying nanoparticles that can cross the BBB so as to deliver medicines in a targeted and controlled way directly to diseased regions of the brain.
A new article published January 17, 2013, in the journal Nanomedicine: Nanotechnology, Biology and Medicine, came about out of a US Federal Bureau of Investigation (FBI) workshop held at the University of Notre Dame (West Bend, IN, USA) in September 2012, tackles this complicated “dual-use” a feature of nanotechnology research.
“The rapid pace of breakthroughs in nanotechnology, biotechnology, and other fields, holds the promise of great improvements in areas such as medical diagnosis and treatment,” said Dr. Kathleen Eggleson, a research scientist in Notre Dame University’s Center for Nano Science and Technology and the author of the study. “But the risk of misuse of these breakthroughs rises along with the potential benefit. This is the essence of the ‘dual-use dilemma.’”
At the same time, the report noted, “nanoparticles designed to cross the BBB constitute a serious threat…in the context of combat.” For instance, it is hypothesized that aerosol delivery of some nanoengineered agent in “a crowded indoor space” could cause serious harm to many people at once. The difficulties presented by dual-use research was highlighted in 2012 when a debate exploded over the publication of findings that indicate how, with several modifications, the H5N1 influenza virus can be altered in a way that would enable it to be transmitted between mammalian populations.
After a self-imposed one-year moratorium on this research, several laboratories worldwide reported that they will resume the research in early 2013. The FBI is actively responding to these advances in the scientific community. “The law enforcement-security community is seeking to strengthen the existing dialogue with researchers,” stated William So, of the FBI’s Biological countermeasures unit. “Science flourishes because of the open and collaborative atmosphere for sharing and discussing ideas. The FBI believes this model can do the same for our two communities [… and] create effective safeguards for science and national interests.”
The scientists and engineers who conduct nanoscale research have the ability and responsibility to consider the public safety features of their research and to act to protect society when necessary, argued Dr. Eggleson. “The relationship between science and society is an uneasy one, but it is undeniable on the whole and not something any individual can opt out of in the name of progress for humanity’s benefit. Thought about dual-use, and action when appropriate, is inherent to socially responsible practice of nanobiomedical science.”
Related Links:
Notre Dame University’s Center for Nano Science and Technology
A new report assessed the potential for nanosized particles to break the blood-brain barrier (BBB), the closely-knit layers of cells that provide the brain with the highest level of protection in the human body. Some neuroscientists are modifying nanoparticles that can cross the BBB so as to deliver medicines in a targeted and controlled way directly to diseased regions of the brain.
A new article published January 17, 2013, in the journal Nanomedicine: Nanotechnology, Biology and Medicine, came about out of a US Federal Bureau of Investigation (FBI) workshop held at the University of Notre Dame (West Bend, IN, USA) in September 2012, tackles this complicated “dual-use” a feature of nanotechnology research.
“The rapid pace of breakthroughs in nanotechnology, biotechnology, and other fields, holds the promise of great improvements in areas such as medical diagnosis and treatment,” said Dr. Kathleen Eggleson, a research scientist in Notre Dame University’s Center for Nano Science and Technology and the author of the study. “But the risk of misuse of these breakthroughs rises along with the potential benefit. This is the essence of the ‘dual-use dilemma.’”
At the same time, the report noted, “nanoparticles designed to cross the BBB constitute a serious threat…in the context of combat.” For instance, it is hypothesized that aerosol delivery of some nanoengineered agent in “a crowded indoor space” could cause serious harm to many people at once. The difficulties presented by dual-use research was highlighted in 2012 when a debate exploded over the publication of findings that indicate how, with several modifications, the H5N1 influenza virus can be altered in a way that would enable it to be transmitted between mammalian populations.
After a self-imposed one-year moratorium on this research, several laboratories worldwide reported that they will resume the research in early 2013. The FBI is actively responding to these advances in the scientific community. “The law enforcement-security community is seeking to strengthen the existing dialogue with researchers,” stated William So, of the FBI’s Biological countermeasures unit. “Science flourishes because of the open and collaborative atmosphere for sharing and discussing ideas. The FBI believes this model can do the same for our two communities [… and] create effective safeguards for science and national interests.”
The scientists and engineers who conduct nanoscale research have the ability and responsibility to consider the public safety features of their research and to act to protect society when necessary, argued Dr. Eggleson. “The relationship between science and society is an uneasy one, but it is undeniable on the whole and not something any individual can opt out of in the name of progress for humanity’s benefit. Thought about dual-use, and action when appropriate, is inherent to socially responsible practice of nanobiomedical science.”
Related Links:
Notre Dame University’s Center for Nano Science and Technology
Latest BioResearch News
- New Findings Clarify Molecular Drivers of Rare Small Intestinal Cancer
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
- Common White Blood Cells Produce Schizophrenia-Linked Protein
- Nanopore Method Captures RNA Folding at Single-Molecule Resolution
- Tumor Microenvironment Marker Linked to Worse Survival in Solid Tumors
- Hidden Immune Gene Defect May Explain Kaposi Sarcoma Susceptibility
- Genetic Markers May Help Predict Amputation Risk in Peripheral Artery Disease
- Gene Signature Shows Promise for Depression Biomarker Testing
- AI-Driven Tumor Profiling Initiative Targets Precision Therapy Development
- Researchers Map Protein and Glycosylation Across 15 Human Body Fluids
- Telomere Length Abnormalities Linked to Lymphoma Development
- Biomarker Signals Chemotherapy Resistance in Relapsed Small Cell Lung Cancer
Channels
Clinical Chemistry
view channel
Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth
Preterm and early-term births can lead to lasting complications because vital organs continue to mature during the final weeks of pregnancy. Babies born too soon face increased risks of breathing difficulties,... Read more
Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia
Primary ciliary dyskinesia is a rare lung disease that affects about one in 7,500 to 10,000 live births worldwide. Symptoms can begin in the newborn period and progress to recurrent respiratory infections... Read more
Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read moreMolecular Diagnostics
view channel
Genetic Testing Identifies High-Risk Patients with Inflammatory Bowel Disease
Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn’s disease, is a lifelong, unpredictable condition that can require advanced therapies or surgery. More than half a million people in the U.... Read more
Ancestry-Informed Genomics Advances Precision Cancer Prognosis
Predicting survival in common cancers remains imprecise despite widespread use of tumor sequencing to guide care. Outcome disparities among patient populations also persist, and the genomic drivers behind... Read more
New Blood Test Predicts Organ-Specific Disease and Mortality Years in Advance
Quantifying organ-specific aging remains a diagnostic challenge, even as age-related disorders drive morbidity and mortality worldwide. Chronological age poorly reflects the physiologic decline that predisposes... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
Persistent symptoms after acute COVID-19 affect millions of people, causing fatigue, respiratory issues, and cognitive deficits that can be difficult to quantify with standard tests. Clinical teams lack... Read moreAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read more
Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read morePathology
view channel
Stain-Free Imaging Platform Matches Standard Cancer Pathology
Histopathology underpins cancer diagnosis, but turnaround times and inter-laboratory variability can limit timely, consistent interpretation. Conventional staining relies on chemical dyes and multiple... Read more
New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools
QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more








